We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 22, 2021

Improved Quality of Life in Men With Prostate Cancer Receiving Abiraterone Compared With Docetaxel

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
J. Clin. Oncol 2021 Nov 10;[EPub Ahead of Print], HL Rush, L Murphy, AK Morgans, NW Clarke, AD Cook, G Attard, A Macnair, DP Dearnaley, CC Parker, JM Russell, S Gillessen, D Matheson, R Millman, CD Brawley, C Pugh, JS Tanguay, RJ Jones, J Wagstaff, S Rudman, JM O'Sullivan, J Gale, A Birtle, A Protheroe, E Gray, C Perna, S Tolan, N McPhail, ZI Malik, S Vengalil, D Fackrell, P Hoskin, MR Sydes, S Chowdhury, DC Gilbert, MKB Parmar, ND James, RE Langley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading